MedTrace Logo

Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative Disorders

NCT07381738 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-02-02

No results posted yet for this study

Summary

This clinical trial is designed as a single-arm, two-center, open-label, prospective study. All participants are enrolled in the standard-dose unrelated umbilical cord blood transplantation group to evaluate the efficacy and safety of unrelated umbilical cord blood transplantation in treating Epstein-Barr virus-associated lymphoproliferative disease.

Conditions

  • Epstein-Barr Virus-associated Lymphoproliferative Diseases
  • Chronic Active Epstein-Barr Virus Infection
  • EBV Associated Lymphoma
  • Umbilical Cord Blood Transplant

Interventions

PROCEDURE

Umbilical cord blood transplantation as treatment of Epstein-Barr virus-associated lymphoproliferative diseases

All participants will be enrolled in the treatment group and will receive a standard-dose unrelated cord blood transplantation. The efficacy and safety of unrelated cord blood transplantation for the treatment of Epstein-Barr virus-associated lymphoproliferative diseases will be evaluated.

Sponsors & Collaborators

  • Huashan Hospital

    collaborator OTHER

  • Fudan University

    lead OTHER

Principal Investigators

  • Jiexian Ma · Huadong Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07381738 on ClinicalTrials.gov